<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="183">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00279214</url>
  </required_header>
  <id_info>
    <org_study_id>9944</org_study_id>
    <secondary_id>F1K-US-EVDA</secondary_id>
    <nct_id>NCT00279214</nct_id>
  </id_info>
  <brief_title>Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock</brief_title>
  <official_title>An Evaluation of Vasopressor Requirement, Hemodynamic Response and Measures of Tissue Perfusion With the Administration of Drotrecogin Alfa (Activated) as Part of Physician-Directed Therapy in Patients With Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the vasopressor requirement, hemodynamic response and measures of
      tissue perfusion in patients with septic shock receiving an infusion of drotrecogin alfa
      (activated) compared to patients not receiving drotrecogin alfa (activated).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cumulative Vasopressor Index (CVI)</measure>
    <time_frame>baseline to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 96 Hour Endpoint in Cumulative Vasopressor Index (CVI)</measure>
    <time_frame>Baseline, 96 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Arterial Pressure</measure>
    <time_frame>baseline to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Performance Measures Obtained With a Pulmonary Artery Catheter - Cardiac Index</measure>
    <time_frame>Baseline to 24 Hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate Level</measure>
    <time_frame>Baseline to 6 Hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microcirculatory Measures From Sidestream Darkfield (SDF) Microscopy - Small Vessel Microvascular Flow Index (MFI)</measure>
    <time_frame>Baseline to 24 Hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) Score at Baseline and 24 Hours</measure>
    <time_frame>Baseline and 24 Hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Creatinine Clearance (CrCl) at 24 Hours</measure>
    <time_frame>Baseline and 24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7 Day All-cause In-hospital Mortality</measure>
    <time_frame>baseline to 7 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endogenous Protein C Level</measure>
    <time_frame>Baseline to 24 Hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mixed Venous Oxygen Saturation</measure>
    <time_frame>Baseline to 24 Hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <enrollment type="Actual">43</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>drotrecogin alfa (activated)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  18 years of age or older with a diagnosis of septic shock

          -  presence of a pulmonary artery catheter (or central venous catheters)

          -  requiring vasopressor support despite adequate fluid resuscitation

          -  an intravenous steroid administered for septic shock, except for those patients who
             were tested and are responders to a corticotropin stimulation test, or patients who
             do not receive a steroid due to the clinical judgment of the treating physician,
             based on an alternate assessment (e.g. normal baseline cortisol).

        Exclusion:

          -  Onset of first-sepsis induced organ dysfunction is greater than 24 hours from the
             time of informed consent

          -  Baseline measurements of pulmonary artery occlusive pressure (PAOP) &lt; 12 mmHg or a
             central venous pressure (CVP) &lt; 8 mmHg

          -  Patient requires continuous oxygen therapy by face-mask

          -  The presence of an advanced directive to withhold life-sustaining treatment, with the
             exception of a directive to withhold chest compressions only

          -  Have received treatment within the last 30 days with a drug that has not received
             regulatory approval for any indication at the time of study entry

          -  Weight &gt; 200 kg

          -  Are moribund (not expected to survive 24 hours)

          -  Are pregnant or are lactating and the milk is to be ingested by the infant (pregnancy
             status must be verified by urine or serum testing)

          -  Have not completed written informed consent signed by the patient or the patient's
             legal representative.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-651-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>August 2009</verification_date>
  <lastchanged_date>August 26, 2009</lastchanged_date>
  <firstreceived_date>December 15, 2005</firstreceived_date>
  <firstreceived_results_date>October 31, 2008</firstreceived_results_date>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Drotrecogin alfa activated</mesh_term>
    <mesh_term>Protein C</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Although 22 and 21 patients were randomized to drotrecogin alfa (activated) [DrotA(a)] and control, respectively, 3 patients in DrotA(a) and 2 patients in control did not receive the per-protocol treatment, and as such, they have been excluded from the baseline demographics and the per-protocol efficacy analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Drotrecogin Cohort</title>
          <description>Group received drotrecogin alfa (activated) per physician-directed therapy</description>
        </group>
        <group group_id="P2">
          <title>Control Cohort</title>
          <description>Group did not receive drotrecogin alfa (activated) per physician-directed therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19">Completed means the number of per-protocol patients in the study</participants>
                <participants group_id="P2" count="19">Completed means the number of per-protocol patients in the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Drotrecogin Cohort</title>
          <description>Group received drotrecogin alfa (activated) per physician-directed therapy</description>
        </group>
        <group group_id="B2">
          <title>Control Cohort</title>
          <description>Group did not receive drotrecogin alfa (activated) per physician-directed therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="38"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="68.0" spread="11.8"/>
                <measurement group_id="B2" value="65.8" spread="15.0"/>
                <measurement group_id="B3" value="66.9" spread="13.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="23"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="38"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>African</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Caucasian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="31"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>East Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Hispanic</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Cardiac Index</title>
          <description>Cardiac Index = cardiac output divided by body surface area.</description>
          <units>liters/minute/meters squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="3.5" spread="1.7"/>
                <measurement group_id="B2" value="3.3" spread="1.4"/>
                <measurement group_id="B3" value="3.4" spread="1.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Creatinine Clearance</title>
          <description>CrCl = (urine creatinine*urine volume)/(plasma creatinine*time period of urine collection). Corrected CrCl = CrCl*1.73/body surface area. Change in CrCl = Endpoint minus baseline.</description>
          <units>milliliter per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="69.2" spread="77.0"/>
                <measurement group_id="B2" value="29.9" spread="31.1"/>
                <measurement group_id="B3" value="52.9" spread="64.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Cumulative Vasopressor Index (CVI)</title>
          <description>CVI is sum of rankings for all vasopressors being used by patient at given time.
Based on relative potency and dosing range for each vasopressor, each vasopressor was assigned ranking of 1 (low dosage) to 4 (high dosage). Range of CVI is between
1 and 20.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="4.3" spread="2.1"/>
                <measurement group_id="B2" value="4.4" spread="2.4"/>
                <measurement group_id="B3" value="4.4" spread="2.2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Lactate Levels</title>
          <description>Measures of global tissue perfusion and oxygenation were assessed via lactate levels.</description>
          <units>millimoles per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="2.0" spread="1.1"/>
                <measurement group_id="B2" value="2.6" spread="2.8"/>
                <measurement group_id="B3" value="2.3" spread="2.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Mean Arterial Pressure (MAP)</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="73.5" spread="9.9"/>
                <measurement group_id="B2" value="72.1" spread="9.4"/>
                <measurement group_id="B3" value="72.8" spread="9.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Mixed Venous Oxygen Saturation</title>
          <description>Cardiovascular performance measures obtained with a pulmonary catheter as assessed by mixed venous oxygen saturation.</description>
          <units>percent saturation mixed venous oxygen</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="68.9" spread="15.6"/>
                <measurement group_id="B2" value="68.9" spread="10.1"/>
                <measurement group_id="B3" value="68.9" spread="12.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Number of Organ Dysfunctions</title>
          <units>number of organ dysfunctions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="2.5" spread="0.8"/>
                <measurement group_id="B2" value="2.0" spread="0.9"/>
                <measurement group_id="B3" value="2.3" spread="0.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ratio of Arterial Partial Pressure of Oxygen to Fraction of Inspired Oxygen (PaO2/FiO2)</title>
          <units>mm Hg / percent inspired oxygen</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="191.8" lower_limit="140.0" upper_limit="260.0"/>
                <measurement group_id="B2" value="248.3" lower_limit="181.7" upper_limit="330.0"/>
                <measurement group_id="B3" value="222.0" lower_limit="164.0" upper_limit="303.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Total Sequential Organ Failure Assessment Score</title>
          <description>The presence of 5 organ dysfunctions (cardiovascular, respiratory, renal, hepatic, coagulation) was assessed using a Sequential Organ Failure Assessment (SOFA) score. Each organ has a possible dysfunction score of 0 to 4, for a total SOFA score range of 0 (no organ dysfunction) to 20 (all organs with dysfunction).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="8.5" spread="2.0" lower_limit="7" upper_limit="10"/>
                <measurement group_id="B2" value="8.3" spread="3.2" lower_limit="6" upper_limit="10"/>
                <measurement group_id="B3" value="8.4" spread="2.6" lower_limit="6" upper_limit="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Vasopressor Index (CVI)</title>
        <description>CVI is sum of rankings for all vasopressors being used by patient at given time. Based on relative potency and dosing range for each vasopressor, each vasopressor was assigned ranking of 1 (low dosage) to 4 (high dosage). Range of CVI is between 1 and 20.</description>
        <time_frame>baseline to 24 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of per-protocol participants with values at baseline and 24 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Drotrecogin Cohort</title>
            <description>Group received drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
          <group group_id="O2">
            <title>Control Cohort</title>
            <description>Group did not receive drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cumulative Vasopressor Index (CVI)</title>
            <description>CVI is sum of rankings for all vasopressors being used by patient at given time. Based on relative potency and dosing range for each vasopressor, each vasopressor was assigned ranking of 1 (low dosage) to 4 (high dosage). Range of CVI is between 1 and 20.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>24 Hour</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.3" spread="2.5"/>
                  <measurement group_id="O2" value="3.0" spread="2.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>24 Hour Change from Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.0" spread="2.2"/>
                  <measurement group_id="O2" value="-1.4" spread="2.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24-Hour p-value</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.238</p_value>
            <method>Repeated Measures - propensity adjusted</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.281</p_value>
            <p_value_desc>24-Hour Change from Baseline p-value</p_value_desc>
            <method>Repeated Measures - propensity adjusted</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 96 Hour Endpoint in Cumulative Vasopressor Index (CVI)</title>
        <description>CVI is sum of rankings for all vasopressors being used by patient at given time. Based on relative potency and dosing range for each vasopressor, each vasopressor was assigned ranking of 1 (low dosage) to 4 (high dosage). Range of CVI is between 1 and 20.</description>
        <time_frame>Baseline, 96 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of per-protocol participants with values at baseline and 96 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Drotrecogin Cohort</title>
            <description>Group received drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
          <group group_id="O2">
            <title>Control Cohort</title>
            <description>Group did not receive drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline to 96 Hour Endpoint in Cumulative Vasopressor Index (CVI)</title>
            <description>CVI is sum of rankings for all vasopressors being used by patient at given time. Based on relative potency and dosing range for each vasopressor, each vasopressor was assigned ranking of 1 (low dosage) to 4 (high dosage). Range of CVI is between 1 and 20.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>96 Hour</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.4" spread="1.3"/>
                  <measurement group_id="O2" value="0.5" spread="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>96 Hour Change from Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.7" spread="2.5"/>
                  <measurement group_id="O2" value="-3.3" spread="2.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.478</p_value>
            <p_value_desc>P-value for 96 Hour Change from Baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Model: Outcome=Therapy + Sedative Indicator + Time + Therapy*Time + Propensity Score</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Arterial Pressure</title>
        <time_frame>baseline to 24 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of per-protocol participants with values at baseline and 24 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Drotrecogin Cohort</title>
            <description>Group received drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
          <group group_id="O2">
            <title>Control Cohort</title>
            <description>Group did not receive drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Arterial Pressure</title>
            <units>mm Hg</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>24 Hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="78.2" spread="11.3"/>
                  <measurement group_id="O2" value="75.6" spread="9.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>24 Hour Change from Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.7" spread="14.6"/>
                  <measurement group_id="O2" value="2.5" spread="12.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.442</p_value>
            <p_value_desc>24-Hour p-value</p_value_desc>
            <method>Repeated Measures - propensity adjusted</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.871</p_value>
            <p_value_desc>24-Hour Change from Baseline p-value</p_value_desc>
            <method>Repeated Measures - propensity adjusted</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiovascular Performance Measures Obtained With a Pulmonary Artery Catheter - Cardiac Index</title>
        <description>Cardiac Index = cardiac output divided by body surface area.</description>
        <time_frame>Baseline to 24 Hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of per-protocol participants with values at baseline and 24 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Drotrecogin Cohort</title>
            <description>Group received drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
          <group group_id="O2">
            <title>Control Cohort</title>
            <description>Group did not receive drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cardiovascular Performance Measures Obtained With a Pulmonary Artery Catheter - Cardiac Index</title>
            <description>Cardiac Index = cardiac output divided by body surface area.</description>
            <units>liters/minute/meters squared</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>24 Hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.3" spread="0.7"/>
                  <measurement group_id="O2" value="3.2" spread="1.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>24 Hour Change from Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.2" spread="1.5"/>
                  <measurement group_id="O2" value="0.1" spread="0.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.704</p_value>
            <p_value_desc>24-Hour p-value</p_value_desc>
            <method>Repeated Measures - propensity adjusted</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.702</p_value>
            <p_value_desc>24-Hour Change from Baseline p-value</p_value_desc>
            <method>Repeated Measures - propensity adjusted</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lactate Level</title>
        <description>Measures of global tissue perfusion and oxygenation were assessed via lactate levels.</description>
        <time_frame>Baseline to 6 Hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of per-protocol participants with values at baseline and 6 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Drotrecogin Cohort</title>
            <description>Group received drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
          <group group_id="O2">
            <title>Control Cohort</title>
            <description>Group did not receive drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Lactate Level</title>
            <description>Measures of global tissue perfusion and oxygenation were assessed via lactate levels.</description>
            <units>millimoles per Liter</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>6 Hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.8" spread="1.0"/>
                  <measurement group_id="O2" value="2.8" spread="4.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 Hour Change from Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.2" spread="0.6"/>
                  <measurement group_id="O2" value="0.4" spread="1.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.061</p_value>
            <p_value_desc>6-Hour p-value</p_value_desc>
            <method>Repeated Measures - propensity adjusted</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.027</p_value>
            <p_value_desc>6-Hour Change from Baseline p-value</p_value_desc>
            <method>Repeated Measures - propensity adjusted</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microcirculatory Measures From Sidestream Darkfield (SDF) Microscopy - Small Vessel Microvascular Flow Index (MFI)</title>
        <description>Per vessel category (and per quadrant), scored flow as follows: no flow=0, intermediate flow=1, sluggish flow=2, continuous flow=3. The MFI per vessel category calculated with formula (Q1+Q2+Q3+Q4)/4. Scores could range from 0 (sluggish flow) to 3 (continuous flow).</description>
        <time_frame>Baseline to 24 Hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of per-protocol participants with values at baseline, 12, and 24 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Drotrecogin Cohort</title>
            <description>Group received drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
          <group group_id="O2">
            <title>Control Cohort</title>
            <description>Group did not receive drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Microcirculatory Measures From Sidestream Darkfield (SDF) Microscopy - Small Vessel Microvascular Flow Index (MFI)</title>
            <description>Per vessel category (and per quadrant), scored flow as follows: no flow=0, intermediate flow=1, sluggish flow=2, continuous flow=3. The MFI per vessel category calculated with formula (Q1+Q2+Q3+Q4)/4. Scores could range from 0 (sluggish flow) to 3 (continuous flow).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.70" spread="0.51"/>
                  <measurement group_id="O2" value="2.50" spread="0.70"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>12 Hour</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.95" spread="0.13"/>
                  <measurement group_id="O2" value="2.80" spread="0.35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>24 Hour</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.56" spread="0.83"/>
                  <measurement group_id="O2" value="2.65" spread="0.47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>24 Hour Change from Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.21" spread="0.61"/>
                  <measurement group_id="O2" value="0.06" spread="0.27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.242</p_value>
            <p_value_desc>Baseline p-value</p_value_desc>
            <method>Repeated Measures - propensity adjusted</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.083</p_value>
            <p_value_desc>12-Hour p-value</p_value_desc>
            <method>Repeated Measures - propensity adjusted</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.810</p_value>
            <p_value_desc>24-Hour p-value</p_value_desc>
            <method>Repeated Measures - propensity adjusted</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.623</p_value>
            <p_value_desc>24-Hour Change from Baseline p-value</p_value_desc>
            <method>Repeated Measures - propensity adjusted</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sequential Organ Failure Assessment (SOFA) Score at Baseline and 24 Hours</title>
        <description>The presence of 5 organ dysfunctions (cardiovascular, respiratory, renal, hepatic, coagulation) was assessed using a Sequential Organ Failure Assessment (SOFA) score. Each organ has a possible dysfunction score of 0 to 4, for a total SOFA score range of 0 (no organ dysfunction) to 20 (all organs with dysfunction).</description>
        <time_frame>Baseline and 24 Hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of per-protocol participants with values at baseline and 24 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Drotrecogin Cohort</title>
            <description>Group received drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
          <group group_id="O2">
            <title>Control Cohort</title>
            <description>Group did not receive drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Sequential Organ Failure Assessment (SOFA) Score at Baseline and 24 Hours</title>
            <description>The presence of 5 organ dysfunctions (cardiovascular, respiratory, renal, hepatic, coagulation) was assessed using a Sequential Organ Failure Assessment (SOFA) score. Each organ has a possible dysfunction score of 0 to 4, for a total SOFA score range of 0 (no organ dysfunction) to 20 (all organs with dysfunction).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.5" spread="2.0"/>
                  <measurement group_id="O2" value="8.3" spread="3.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>24 Hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.8" spread="2.3"/>
                  <measurement group_id="O2" value="7.8" spread="4.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.686</p_value>
            <p_value_desc>Baseline p-value</p_value_desc>
            <method>Repeated Measures - propensity adjusted</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.575</p_value>
            <p_value_desc>24-Hour p-value</p_value_desc>
            <method>Repeated Measures - propensity adjusted</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Creatinine Clearance (CrCl) at 24 Hours</title>
        <description>CrCl = (urine creatinine*urine volume)/(plasma creatinine*time period of urine collection). Corrected CrCl = CrCl*1.73/body surface area. Change in CrCl = Endpoint minus baseline.</description>
        <time_frame>Baseline and 24 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of per-protocol participants with values at baseline and 24 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Drotrecogin Cohort</title>
            <description>Group received drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
          <group group_id="O2">
            <title>Control Cohort</title>
            <description>Group did not receive drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Creatinine Clearance (CrCl) at 24 Hours</title>
            <description>CrCl = (urine creatinine*urine volume)/(plasma creatinine*time period of urine collection). Corrected CrCl = CrCl*1.73/body surface area. Change in CrCl = Endpoint minus baseline.</description>
            <units>milliliter per minute</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-9.74" spread="75.45"/>
                  <measurement group_id="O2" value="1.66" spread="28.90"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.165</p_value>
            <method>Repeated Measures - propensity adjusted</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>7 Day All-cause In-hospital Mortality</title>
        <time_frame>baseline to 7 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>All enrolled patients</population>
        <group_list>
          <group group_id="O1">
            <title>Drotrecogin Cohort</title>
            <description>Group received drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
          <group group_id="O2">
            <title>Control Cohort</title>
            <description>Group did not receive drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>7 Day All-cause In-hospital Mortality</title>
            <units>partipants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Alive at 7 Days</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Not Alive at 7 Days</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endogenous Protein C Level</title>
        <time_frame>Baseline to 24 Hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of per-protocol participants with values at baseline, 12, and 24 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Drotrecogin Cohort</title>
            <description>Group received drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
          <group group_id="O2">
            <title>Control Cohort</title>
            <description>Group did not receive drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Endogenous Protein C Level</title>
            <units>percentage of Protein C activity</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="38.7" spread="25.2"/>
                  <measurement group_id="O2" value="34.8" spread="19.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>12 Hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48.2" spread="23.0"/>
                  <measurement group_id="O2" value="38.9" spread="19.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>24 Hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="54.7" spread="20.7"/>
                  <measurement group_id="O2" value="40.0" spread="17.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>24 Hour Change from Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.3" spread="16.2"/>
                  <measurement group_id="O2" value="2.4" spread="16.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.552</p_value>
            <p_value_desc>Baseline p-value</p_value_desc>
            <method>Repeated Measures - propensity adjusted</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.129</p_value>
            <p_value_desc>12-Hour p-value</p_value_desc>
            <method>Repeated Measures - propensity adjusted</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.030</p_value>
            <p_value_desc>24-Hour p-value</p_value_desc>
            <method>Repeated Measures - propensity adjusted</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.002</p_value>
            <p_value_desc>24-Hour Change from Baseline p-value</p_value_desc>
            <method>Repeated Measures - propensity adjusted</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Bleeding Events</title>
        <description>Serious bleeding event resulted in one of following outcomes, or was significant for any reason: initial/ prolonged inpatient hospitalization; life-threatening experience; persistent or significant disability/incapacity; congenital anomaly/birth defect. Intracranial hemorrhage was also considered serious bleeding event.</description>
        <time_frame>baseline to 7 days</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>All enrolled patients</population>
        <group_list>
          <group group_id="O1">
            <title>Drotrecogin Cohort</title>
            <description>Group received drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
          <group group_id="O2">
            <title>Control Cohort</title>
            <description>Group did not receive drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Bleeding Events</title>
            <description>Serious bleeding event resulted in one of following outcomes, or was significant for any reason: initial/ prolonged inpatient hospitalization; life-threatening experience; persistent or significant disability/incapacity; congenital anomaly/birth defect. Intracranial hemorrhage was also considered serious bleeding event.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Serious Bleeding Event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Intracranial Hemorrhage</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mixed Venous Oxygen Saturation</title>
        <description>Cardiovascular performance measures obtained with a pulmonary catheter as assessed by mixed venous oxygen saturation.</description>
        <time_frame>Baseline to 24 Hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of per-protocol participants with values at baseline and 24 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Drotrecogin Cohort</title>
            <description>Group received drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
          <group group_id="O2">
            <title>Control Cohort</title>
            <description>Group did not receive drotrecogin alfa (activated) per physician-directed therapy</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mixed Venous Oxygen Saturation</title>
            <description>Cardiovascular performance measures obtained with a pulmonary catheter as assessed by mixed venous oxygen saturation.</description>
            <units>percent saturation mixed venous oxygen</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>24 Hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="69.6" spread="8.3"/>
                  <measurement group_id="O2" value="75.0" spread="11.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>24 Hour Change from Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.7" spread="14.5"/>
                  <measurement group_id="O2" value="6.5" spread="13.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.128</p_value>
            <p_value_desc>24-Hour p-value</p_value_desc>
            <method>Repeated Measures - propensity adjusted</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.234</p_value>
            <p_value_desc>24-Hour Change from Baseline p-value</p_value_desc>
            <method>Repeated Measures - propensity adjusted</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Drotrecogin Cohort</title>
          <description>Group received drotrecogin alfa (activated) per physician-directed therapy</description>
        </group>
        <group group_id="E2">
          <title>Control Cohort</title>
          <description>Group did not receive drotrecogin alfa (activated) per physician-directed therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4"/>
                <counts group_id="E2" subjects_affected="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (10.0)">Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Right sided hemothorax</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (10.0)">Hemorrage intraperitoneal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4"/>
                <counts group_id="E2" subjects_affected="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (9.1)">Gross hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (10.0)">Oropharynx blood and ecchymoses</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>1-800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
